T1	eligibility 66 139	postmenopausal women with hormone receptor-positive advanced breast cance
T3	outcome-Measure 795 820	progression-free survival
T4	control 713 720	placebo
T5	total-participants 763 766	724
T7	total-participants 1069 1072	720
T8	intervention-participants 1094 1097	482
T9	control-participants 1110 1113	238
T11	outcome 1392 1406	dose reduction
T12	outcome 1411 1423	interruption
T13	iv-bin-abs 1425 1428	360
T14	iv-bin-abs 1433 1436	705
T15	outcome 1572 1587	Discontinuation
T16	iv-bin-percent 1650 1652	9%
T17	cv-bin-percent 1672 1674	3%
T2	intervention 696 699	EVE
T18	outcome 1523 1559	median duration of dose interruption
T6	outcome-Measure 852 868	overall survival
T19	outcome-Measure 870 893	objective response rate
T20	outcome-Measure 899 905	safety
T10	outcome 1187 1197	stomatitis
T21	outcome 1199 1210	pneumonitis
T22	outcome 1216 1229	hyperglycemia
